In October 2024, Xiaolin attended the annual AAPS 2024 PHARMSCI 360 in Salt Lake City, where industry and academia showcased research across pharmaceutical science, including discovery, preclinical studies, drug delivery, and analytical research. She presented our recent progress in developing a long-acting gemcitabine and paclitaxel drug combination nanoparticle for orthotopic breast cancer treatment. Her poster presentation, titled “A Stable and Scalable Gemcitabine and Paclitaxel Drug Combination Nanoparticle (DcNP) Exhibits Long-Acting Pharmacokinetics and Breast Tumor Regression in an Orthotopic 4T1 Mouse Model,” highlighted the nanoparticle’s extended pharmacokinetics and tumor regression efficacy.
